Polymorphic changes in the GSTM1, CYP2E1 and the CYP2D6 genes have been reported to be individually associated with increased susceptibility to certain cancers. In the present study, the relationship between genetic polymorphism for these genes and development of urinary bladder cancer among Egyptian patients was investigated. Our results indicate that the frequency of bladder cancer patients with the GSTM1 null genotype is significantly higher than that of the normal controls (86.3 and 47.6%, respectively) with an odds ratio (OR) of 6.97 (95% CL = 1.59-30.57, Fisher's exact P = 0.008). In contrast, our investigation failed to demonstrate any difference in the distribution of CYP2E1 polymorphism between bladder cancer patients and controls as detected by PstI restriction fragment length polymorphism (RFLP) analysis. RFLP analysis of the CYP2D6 gene revealed a non-significant increase in the number of extensive metabolizers (EM) among the patients compared to the controls (68 versus 48%). However, the EM genotypes enhances the risk further for individuals harboring the GSTM1 null genotype as individuals harboring both the EM and the GSTM1 null genotypes have an odds ratio of 14.0 (95% CL = 13-151.4, Fisher's exact P = 0.02) compared to individuals harboring the EM and the GSTM1+/+ genotypes. In conclusion, our results indicate that genetic polymorphism, especially in GSTM1 and CYP2D6 could play an important role as host risk factors for development of urinary bladder cancer among Egyptians.
Introduction
Urinary bladder cancer is a common neoplasm around the world. It is the fifth most common cancer in the United States, accounting for over 51 000 new cases in 1994(1). In developing countries such as Egypt, it constitutes 30.8% of total cancer incidence and ranks first among all types of cancer reported in males and second only to breast cancer in females (2) . Therefore, understanding the etiology and mechanisms for development of this malignancy is of high priority for reduction of human sufferings.
•Abbreviations: OR, odds ratio; NNC, Af-nitroso-compounds; PM, poor metabohzer; CYP2D6, cytochrome P450 2D6 gene; RFLP, Oral restriction fragment length polymorphism; GSTM1, glutathione-S-transferase Ml; PCR, polymerase chain reaction; EM, extensive metabolizers; HEM, heterozygous extensive metabolizers; CL, confidence limits; BCNU, 3-bis(2-chloroethyl)-1-nitrosourea.
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In Egypt, the majority of bladder cancer is associated with Schistosoma haematobium infection (2) (3) (4) (5) (6) (7) (8) . Such infection causes inflammation of the urinary bladder epithelium. It is believed that the induced proliferating cells become more susceptible to mutagenic insults from environmental toxicants such as Af-nitroso-compounds (NNC*) (9) (10) (11) . Continued exposure to toxicants and clonal expansion of the damaged cells in the bladder will increase the likelihood of cancer development (12) . Consistent with this hypothesis, NNC have been detected in the urine of schistosoma patients, including those with bladder cancer, at levels significantly higher than in uninfected subjects (10, 12, 13) and these toxicants have also been demonstrated to induce cancer in schistosoma-infected baboons (9) .
Most chemical carcinogens are not capable of inducing genetic damage by themselves but require metabolic activation to electrophilic proximate carcinogens, which can cause mutations. The amount of the ultimate carcinogens produced depends on the action of competing activation and detoxication pathways involving cytochrome P450 and glutathione-S-transferase enzymes (14) (15) (16) . Genetic differences in these pathways are likely to be a major source of interindividual variations in susceptibility to cancer (17) (18) (19) . For example, the poor metabolizer (PM) phenotype of the cytochrome P450 2D6 gene (CYP2D6) is associated with reduced bladder cancer susceptibility indicating that the enzyme may be involved in the conversion of procarcinogens to proximate carcinogens (20) (21) (22) . Although CYP2D6 protein has not been detected in urinary bladder, consistent with this hypothesis, a direct correlation between CYP2D6 genotype and the concentration of the CYP2D6 mRNA was observed in the target bladder mucosa (23) . The exact mechanism by which CYP2D6 is involved in schistosoma] bladder cancer remains to be characterized.
Genetic polymorphism in CYP2E1 is another contributing cancer risk factor since this enzyme activates a number of small molecular weight compounds including NNC (24) (25) (26) (27) , which are known bladder carcinogens. A Dral restriction fragment length polymorphism (RFLP) of CYP2E1 is associated with an increased risk of lung cancer in Japanese (28) . This finding, however, is not confirmed in Western populations (29) (30) (31) . The difference may be due to ethnic differences in distribution of the mutated gene. Furthermore, it is not known if polymorphism in this enzyme may constitute a potential risk factor in schistosomal bladder cancer.
While oxidation by CYP450 enzymes is primarily regarded as the phase-I activating process in carcinogenesis (32) , most phase-II metabolizing enzymes, e.g. glutathione-S-transferase Ml (GSTM1) are considered to be predominantly protective enzymes since they detoxify a number of reactive chemical carcinogens (16, 33) . The gene is polymorphic in humans, and the deficiency in enzyme activity is caused by an inherited homozygous deletion of the gene (GSTM1 0/0) (34) (35) (36) . With the exception of a recent report (37) , many studies indicate that GSTM1 deficiency is correlated with bladder cancer (38) (39) (40) . No reports, however, has been found in the literature regarding GSTM1 gene deficiency and schistosomal bladder cancer risk.
In the present study, the genetic alterations in GSTM1, CYP2E1 and CYP2D6 genes were investigated in an Egyptian bladder cancer population. Our results indicate that genetic polymorphisms in GSTM1 and CYP2D6 but not CYP2E1 could be important host risk factors for urinary bladder cancer among Egyptians.
Materials and methods

Study subjects
The target group consisted of 22 Egyptian bladder cancer patients (18 male and 4 females) (mean age ± SD = 58.6 ± 8.3). As part of the medical survey, all study subjects were interviewed to obtain their demographic data and health and smoking history. Among these patients, 19 (86.3%) had clinical or self-reported history of schistosomiasis. Their bladder cancers were histologically verified. The control group consisted of 21 normal individuals (13 males and 8 females) who were matched to the cases with respect to the range of age and smoking history. The normal controls had no history of schistosoma infection nor malignancies. To avoid confounding factors due to ethnic differences in GSTM1 (41), CYP 2D6 (42) and CYP2E1 (31) , only Egyptians were included in the study.
Chemicals and reagents
All primers used for polymerase chain reaction (PCR) analysis were custom synthesized by the Recombinant DNA Laboratory, Sealy Center for Molecular Sciences, University of Texas Medical Branch, Galveston, TX. All other chemicals and reagents were from commercial sources and were of the highest purity available as described in each experimental procedure.
DM4 Isolation
Normal and tumor bladder tissues were removed from bladder cancer patients by cystoscopy or surgery at the National Cancer Institute, Cairo, Egypt. Peripheral blood samples were obtained from normal controls. DNA was isolated from normal or tumor bladder tissues of patients and from peripheral blood lymphocytes of controls by a non-organic DNA extraction procedure as previously described (43) or by the conventional phenol-chloroform extraction method (44) . Isolated DNA was resuspended in Tris-EDTA buffer (10 mM Tris, 1 mM EDTA, pH 8.2). Isolated DNA and frozen tissues were sent by courier express mail from Egypt to our laboratory in the United States. Upon arrival, samples were stored at -70°C until use.
Genotype analysis by polymerase chain reaction (PCR) GSTM1 genotyping. The presence or absence of the GSTM1 gene was determined using a modification of a differential PCR approach described previously (38) . Briefly, 50-100 ng of isolated DNA was added to a PCR reaction mixture composed of 30 pmol of each GSTM1 pnmer Gl-5'GAA CTC CCT GAA AAG CTA AAG C; G2-5'GTT GGG CTC AAA TAT ACG GTG G, 10 pmol of each (J-globin gene primers used as internal positive control (Pl-5'CAA CTT CAT CCA CGT TCA CC and p2-5'GAA GAG CCA AGG ACA GGT AC), 200 umol dNTPs, 2 U Taq DNA polymerase (Promega, Madison, WI), 5 ul of 10XPCR buffer (10X: 500 mM KC1, 100 mM Tris-HCl, pH 9.0) and 1.5 mM MgCl 2 in a final volume of 50 ul. In a programmable thermal controller (PTC, MJ Research Inc., Watertown, MA), an initial melting temperature of 94*C (2 min) was followed by 30 cycles of melting (94°C, 2 min), annealing (55°C, 1 min) and extension (72°C, 1 min). A final 72°C extension for 3 min was performed. The PCR products from coamplification of GSTM1 (215 bp) and pVglobin (268 bp) were then electrophoresed on an ethidium bromide-stained 2% 3:1 Nusieve Agarose gel (FMC Bioproducts, Rockland, Maine). All assays were done in duplicate. The replication rate was 100% except in rare cases when one of the tubes completely failed to amplify, as judged by the internal control amplification.
RFLP analysis of CYP2E1. The method described by Kato et al (30) was used for RFLP analysis of CYP2E1. A PCR procedure was used to amplify the transcription regulation region of CYP2E1 that includes a Pstl restriction site of the gene (45) . In a total reaction volume of 50 uj, genomic DNA (100 ng) was amplified with primers (0. 
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Watertown, MA), an initial denaturation step (95°C, lmin) was followed by 25 cycles of 95°C for 1 min, 55°C for 1 min and 72°C for 1 min. After the last cycle, the temperature was held at 72°C for 4 min. 25 ul of the PCR product was then digested overnight at 37°C with 10 U Pstl restriction enzyme (New England Biolabs Inc., Beverly, MA) in buffer (50 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl 2 , 1 mM dithiothreitol, pH 8.3). The samples were then analyzed on an ethidium bromide stained 1.5% agarose gel. The presence of a Pstl restriction site, indicative of a mutant allele, is shown by two fragments of 120 and 290 bp. In each experiment, a homozygous wild type (Pstl negative) as well as a mutant (Pstl positive) were used as controls and all assays were done in duplicate.
RFLP analysis of CYP2D6. Three gene-inactivating mutations have been identified in the CYP2D6 gene, a G to A transition at the junction of intron 3 and exon 4 (mutation 1; allele known as 2D6B), a base pair deletion in exon 5 (mutation 2; allele known as 2D6A) and a total gene deletion (allele known as 2D6D) (46) (47) (48) (49) . In the normal CYP2D6 gene, there is an ScrFI (BstNl) restriction site (CCNGG) at the boundary that is lost in individuals with the G to A transition. As a consequence, these restriction enzymes will not cut the genomic DNA in PMs with the mutation at this position. This technique described for the G-to-A transition cannot be directly applied to the analysis of the base pair deletion mutation in exon 5 because of the lack of a suitable restriction site. However, by using appropriately designed mismatched oligonucleotides for the PCR, it is possible to introduce a Dralll restriction site that could be used for the detection of this mutation. In the present study, a modification of the PCR-based single tube assay developed by Spurr et al. (50) was used to analyze the mutations of the CYP2D6 gene. The PCR reaction was carried out using the primers designed by Spurr et al. (50) . Primer A (5'-TGC CGC CTT CGC CAA CCA CT-3', BP 1824-1843) hybridizes to exon 3 of the CYP2D6 gene sequence and pnmer B with specially introduced mismatched base pairs (underlined italic letters) (5'-GGC TGG GTC CGA GGT CAC CC-3', bp 2657-2638) hybridizes to exon 5. In addition to these primers two more primers specific for the pseudogene CYP2D8, C(5'-CGG CCC AGC CAC TCT CGT GT-3', bp 5141-5160) and D(5'-AAC AGG GTC CCA GCT GAG GAG-3', bp 5241-5221) were included into the reaction mixture as an internal control. The PCR amplification reaction components typically contained 50-100 ng DNA, 6% (W/V) DMSO, 2 mM MgCl 2 , 0.25 uM of each primer A and B, 0.125 uM of each primer C and D, 200 umol dNTPs and 5 U of Amplitaq DNA polymerase (Roche Molecular Systems, Inc., Branchburg, NJ, USA) in a total volume of 50 ul. Following an initial denaturation at 94°C for 3 min, 30 cycles of PCR were carried out at 94°C for 1 min, 60°C for 1 min and 72°C for 1 min. A final polymerization step of 72°C for 4 min is added at the end. All the PCR products were then digested with three units of Drain (New England Biolabs, Beverly, MA) and 2 U of ScrFI (New England Biolabs, Beverly, MA) in the presence of 100 Hg/ml BSA and digestion buffer (10 mM NaCl, 5 mM Tn-HC1, 1 mM MgCl 2 , 0.1 mM DTT, pH 7.9) at 37°C under oil for 3 h. 50 ul of the reaction mixture was electrophoresed on an ethidium bromide stained 3.5% Metaphore agarose gel (FMC bioproducts, Rockland, ME) for 4 h at 45 V. The assay was performed at least twice for each sample. Using this technique, it was possible to differentiate between the homozygous extensive metabolizers (EM), the heterozygous extensive metabolizers (HEM) as well as the different types of PMs. PMs include individuals who were homozygous for the gene deletion (PM1), where only the internal control (CYP2D8) was amplified, individuals heterozygous for mutation 1 and mutation 2 (PM2) and individuals homozygous for mutation 2 or heterozygous for the gene deletion and mutation 2 (PM3).
Statistical analysis
The Fisher's exact test was used to test the association between bladder cancer status and geneuc polymorphisms in GSTM1, CYP2E1 and CYP2D6 genes. Odds ratio (OR) and 95% confidence limits (CL) were used to describe the strength of the association (51).
Results
GSTM1 genotyping
As shown in Figure 1 , the differential PCR method adopted in our study allowed an internal standard-controlled classification of the different GSTM1 genotypes (GSTM1 +/+, +/0 and 0/0). In our study, only one out of 22 bladder cancer cases and one out of the 21 controls were found to be heterozygous for GSTM1 (GSTM1 +/0). Since GSTM1 +/0 and GSTM1 +/+ genotypes were reported to possess similar enzyme expression (38) , these individuals were grouped among those with the +/+ genotype. The rest of the cases and controls were homozygous for GSTM1 0/0 or GSTM1 +/+. As shown in Table I , 19 bladder cancer cases (86.3%) were classified as heritably GSTM1 deficient (GSTM1 0/0), a proportion that is significantly higher than the GSTM1 0/0 observed in the corresponding controls (47.6%), with an OR of 6.97 (95% CL = 1.59-30.57, Fisher's exact P = 0.008). Our results indicate a significant difference in GSTM1 genotype frequency between bladder cancer patients and controls.
RFLP analysis of CYP2EJ
Polymorphisms in CYP2E1 were detected by the presence or absence of the Pstl restriction site located within the transcription regulation region of the CYP2E1 gene (45) . Amplified PCR products from all the bladder cancer patients digested with Pstl showed only one band at 410 bp when analyzed by agarose gel electrophoresis and were therefore classified as Pstl homozygous wild type, while among the controls, only one case was Pstl heterozygous (Figure 2 ). There was no statistical difference in the distribution of CYP2E1 polymorphisms between patients and controls (Fisher's exact P = 0.48) ( Table I) .
RFLP analysis of CYP2D6
Among the 22 bladder cancer patients studied, ten were homozygous EM and five patients were heterozygous extensive metabolizers (HEM), therefore, 68% of the patients were classified as extensive metabolizers. There were also seven PM patients; three were homozygous for the gene deletion (PM1), three patients were either homozygous for the bp deletion in exon 5 or heterozygous for the bp deletion mutation and the G-to -A transition mutation (PM2) and one patient was either homozygous for the bp deletion mutation or heterozygous for gene deletion and the bp deletion mutation (PM3). Ten controls (48%) were classified as extensive metab- olizers. Six of them were EM and four were HEM. The remaining 11 controls were PM; four were PM1 and five were PM2. The remaining two PM controls were PM3. Although the distribution of EM genotypes in patients (n = 15) was not statistically different from that of healthy controls (n = 10) (Fisher's exact P = 0.145), an OR of 2.36 (95% CL = 0.68-9.9) reflected a modest increase in risk associated with EM genotypes (Table I ). The same observation was true for the distribution of PM genotypes, where no statistical difference between patients and controls was detected although a modest under representation in the number of PM patients relative to the controls was observed (7 patients versus 11 controls) ( Table I ). There was no difference in the allelic frequency in EM and PM genotypes among patients and controls (Table I) .
Combined polymorphisms and bladder cancer risk
To further elucidate the genetic factors associated with cancer risk, the role of combined genetic polymorphisms in the CYP2D6 and GSTM1 genes was investigated. Four genetic combinations were possible and individuals were classified into four groups as follows: PM/GSTM1+/+ individuals (group A), PM/GSTM1 0/0 individuals (group B), EM/GSTM1 +/+ individuals (group C) and EM/GSTM1 0/0 individuals (group D). The OR and the Fisher's exact-test were calculated to estimate the relative risk associated with each genetic combination (Table II) . The results indicated that EM with the GSTM1 null genotype (group D) are at a significantly higher relative risk to develop bladder cancer than EM individuals harboring the GSTM1 +/+ genotype (group C) (OR = 14; 95% CL = 1.3-51.4; Fisher's exact P = 0.02). Furthermore, there was an increased relative risk associated with EM/ GSTM1 0/0 genotypes (group D) relative to PM/GSTM1 +/ + genotypes (group A) (OR = 8.4 ; 95% CL = 1.26-56.03, Fisher's exact P = 0.02). In contrast, there was no significant increase in relative risk associated with the other genetic combinations compared to each other (group B compared to group A, group D compared to group B, group B compared to group C and group A compared to group C).
Discussion
The ability to characterize polymorphic genes involved in metabolism of carcinogens has opened up a new approach for human cancer risk assessment (52) (53) (54) . In the present work, CYP2D6, CYP2E1 and GSTM1 were studied as indicators of C CYP2D6 polymorphism is classified into poor metabolizers (PM) and extensive metabolizers (EM). PMs were further classified into PM 1 (homozygous for gene deletion), PM2 (heterozygous for mutation 1 and mutation 2) and PM3 (heterozygous for the gene deletion and mutation 2 or homozygous for mutation 2) (see Materials and methods). EM were further classified into HEM (one wild type allele and a G-to -A transition mutation (mutation 1) on the second allele or one wild type allele and a bp transition mutation (mutation 2) on the second allele) and EM (homozygous wild type). ''Comparison between extensive metabolizers (EM + HEM) and poor metabolizers (PM1 + PM2 + PM3). C OR represents the relative risk for bladder cancer for individuals with the GSTMl null genotype relative to those with GSTMl +/+ and for CYP2D6 PM genotypes relative to those with EM genotypes. NA, Not determined due to cell with zero value in 2X2 table (Fisher's exact-test). host risk factors among Egyptian bladder cancer patients. The results of our study clearly demonstrate a strong association between GSTMl null genotype and bladder cancer risk. While the allelic distribution of the GSTMl null genotype in our control group (47.6%) is consistent with reports in different populations (34, 38, 55, 56) , the distribution of GSTMl null genotype in bladder cancer patients (86.3%) is significantly higher than the control and is therefore indicative of significantly increased bladder cancer risk (OR = 6.97, 95% CL= 1.59-30.57, Fisher's exact P = 0.008). The GSTMl null genotype has also been associated with bladder cancer among non-Egyptians having no history of schistosomal infection (38) . Interestingly, the frequency of the genotype in bladder cancer reported in these studies is similar to those reported in gastrointestinal malignancy (57) and lung cancer (36) . Such association clearly indicates the important role of GSTMl in the development of cancer.
The majority of our patients had a history of schistosomal infection. Since increased levels of NNC were reported in schistosoma-infected patients (10, 12, 13) , our data suggest that the GSTMl gene product glutathione-S-transferase (i plays a role in the detoxication of bladder carcinogens such as NNC. This is consistent with the fact that the NNC, l,3-bis(2-chloroethyl)-l-nitrosourea (BCNU), is a substrate for glutathione-S-transferase (i class enzymes in the rat (58) and with the assumption that alkylating agents such as jV-nitrosamines may be targets for the glutathione-S-transferase u. protective effect (38) .
GSTMl enzyme would also play a protective role in the bladder by preventing the formation of NNC. The increased susceptibility of the GSTMl null individuals may result from impaired detoxication of reactive oxygen species (59), such as those involved in the formation of NNC. Indeed, it has been reported that NNC can be synthesized endogenously by enzymatic reactions as well as by activated macrophages and neutrophils resulting from inflammatory processes such as those accompanying schistosomal infection (60) . The latter two cell types generate, via nitric oxide synthase, the nitric oxide radical that is involved in the formation of carcinogenic nitrosamines (61) . Consistent with this hypothesis, it has been suggested that GSTMl null individuals would be more susceptible to oxidative stress-induced damage during inflammation, a process that may progress to malignancy particularly following free-radical mediated activation of potential procarcinogens (62) .
In contrast to the association between GSTM1 null genotype and increased risk to bladder cancer, our study failed to demonstrate an association between CYP2E1 Pstl polymorphism and increased risk for the disease. This CYP2E1 polymorphism has not been studied extensively in relation to human carcinogenesis. It should be noted, however, that the frequency of Pstl mutant individuals in the Egyptian population is currently unknown. With the exception of Japanese, a low frequency of Pstl mutant individuals among Caucasians (2%) and African-Americans (5%) has been reported (30) . Given the small number of the samples studied and the unknown background allelic frequency of the Pstl RFLP at the CYP2E1 gene locus in Egyptian population, the statistical power of the present study is limited and a larger sample size will be required to definitively test the association. It is noteworthy to mention that another polymorphism, located at intron 6 of the CYP2E1 gene locus revealed by a Dral restriction site was associated with increased lung cancer risk in Japanese people (28) . This polymorphism has not been determined in the current study and therefore is warranted, on a larger scale, before an association between CYP2E1 polymorphism and bladder cancer risk among Egyptians can be better defined.
The method we used for the genotypic analysis of the CYP2D6 polymorphism allowed us to identify the wild type homozygous extensive metabolizers (EM), the heterozygous extensive metabolizers (HEM) and poor metabolizers (PM) unequivocally. This method also has the advantage for further subclassification of the HEMs and the PMs into different subtypes according to the harbored mutations in a single assay. Our results indicate an increase in the number of extensive metabolizers in bladder cancer patients relative to the controls. Although the increase is not statistically significant, these data support the previous findings that polymorphism at the CYP2D6 locus is associated with susceptibility to nonschistosomal bladder cancer (20, 21) . It has been suggested that carcinogens that induce urinary bladder cancer are converted by hepatic drug metabolizing enzymes to products that are excreted in the urine. Hydrolysis of these metabolites in the urine would result in the release of the proximate carcinogens and induction of bladder cancer (63, 64) . The fact that schistosomes mature in the liver and inhabit the hepatic portal venous system before migrating to the definitive organ (65) may explain the increased risk associated with the homozygous extensive metabolizer phenotypes. It has been reported that during this period of the life cycle of the parasite, higher levels of alkylating reactive intermediates are produced as a result of the associated alteration in the carcinogenic metabolizing pathways in the infected liver (66) . These reactive carcinogenic metabolites not only can damage bladder DNA, but also as recently demonstrated, liver DNA (67-69). Alternatively, it is possible that drug metabolizing enzymes within the transitional cells of the bladder can directly form proximate carcinogens from procarcinogens. This possibility is substantiated by the recent finding that human bladder mucosa expresses CYP2D6 mRNA in a manner highly correlated with debrisoquine hydroxylase activity which raises the possibility that constitutive drug metabolizing enzyme activity is a major determinant for the risk of developing bladder cancer (23) . In view of the reported role of CYP2D6 in the conversion of procarcinogens to proximate carcinogens (20) (21) (22) it is logical to assume that extensive metabolizers would be more at risk of developing schistosoma-associated bladder cancer since they would produce more of such alkylating reactive intermediates than poor metabolizers.
The results of our study indicate an ethnic difference in the allelic frequency of the CYP2D6 genotypes compared to that previously reported in the literature for Caucasians, Chinese, Zimbabwe and Black Americans (for review see Reference 42). Among our Egyptian control population studied, 48% were classified as extensive metabolizers (EM and HEM) as compared to a reported range of 56-94% extensive metabolizers in different ethnic populations (42) . This implies an over-representation of the PM genotypes in Egyptian population as compared with that previously reported in the literature (42, (70) (71) (72) (73) . The PM1 genotype (total gene deletion) accounted for 36% of all the detected PM genotypes in our control population and 43% of all PMs in our bladder cancer patients. This value is significantly higher than the percentage of PM1 reported in the literature (42, (70) (71) (72) (73) . This unusual observation is unlikely to be due to technical error. Using the same technique for CYP2D6 polymorphism analysis in our laboratory we observed a similar allelic distribution in a North American population compared to that reported in the literature (unpublished data). In addition, the results from our internal PCR controls is consistent with expectations. Nevertheless, a larger population needs to be studied in order to rule out the chance confounding factor.
The majority of the reports found in the literature have focused on the study of polymorphism of a single gene in relation to cancer risk without considering variations in other metabolizing enzymes genes. In an effort to elucidate what constitutes the highest risk subpopulation, investigators have recently studied the risk for cancer in individuals harboring multiple polymorphisms (74) . The results of our study indicate that there is a 7-fold increase in risk for development of bladder cancer among individuals harboring the GSTM1 null genotype than individuals who harbor the GSTM1 47+ genotype (OR = 6.97; 95% CL = 1.59-30.57). The risk is further increased in the presence of the EM genotype (OR = 14; 95% CL = 1.3-151.4 for EM with GSTM1 0/0 versus EM with GSTM1 +/+). In addition, the relative risk in EM individuals harboring the GST null genotype compared to PM harboring the GST+/+ genotype is also increased (OR = 8.4; 95% CL = 1.26-56.03). Studies are ongoing in our laboratory with expanded populations and with additional polymorphic genes to better define the relationship between genetic predisposition and bladder cancer. Effort is made to recruit additional non-schistosomal bladder cancer patients as well as non-cancer patients with schistosoma infection. This would allow an assessment of the role of the genotypes in bladder cancer without confounding by the suspected promoting agent. Our study clearly supports the use of combined genotypic analysis of different metabolizing genes for the estimation of individual risk for cancer development.
In conclusion our results indicate that CYP2E1 does not seem to play a major role in schistosomal bladder cancer. Although our studied population is small, our data indicate that polymorphisms for CYP2D6 and GSTM1 genes should be considered as important risk modifiers considered in the development of schistosomal bladder cancer among Egyptians and should be further investigated.
